메뉴 건너뛰기




Volumn 33, Issue 5, 2013, Pages 496-514

To RAS or Not to RAS? The evidence for and cautions with Renin-Angiotensin system inhibition in patients with diabetic kidney disease

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Diabetic kidney disease; Renin angiotensin system inhibition

Indexed keywords

ALBUMIN; ALDOSTERONE; ALISKIREN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CREATININE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LOSARTAN; OLMESARTAN; PLACEBO; POTASSIUM; RAMIPRIL; RENIN; RENIN INHIBITOR; TELMISARTAN;

EID: 84879600350     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1232     Document Type: Review
Times cited : (27)

References (78)
  • 1
    • 84871995815 scopus 로고    scopus 로고
    • Standards of medical care in diabetes 2013
    • American Diabetes Association
    • American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes Care 2013;36(Suppl 1):S11-S66.
    • (2013) Diabetes Care , vol.36 , Issue.SUPPL. 1
  • 3
    • 79959487586 scopus 로고    scopus 로고
    • Temporal trends in the prevalence of diabetic kidney disease in the United States
    • De Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532-2539.
    • (2011) JAMA , vol.305 , pp. 2532-2539
    • De Boer, I.H.1    Rue, T.C.2    Hall, Y.N.3    Heagerty, P.J.4    Weiss, N.S.5    Himmelfarb, J.6
  • 4
    • 0029076841 scopus 로고
    • Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial
    • The Diabetes Control and Complications (DCCT) Research Group
    • The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995;47:1703-1720.
    • (1995) Kidney Int , vol.47 , pp. 1703-1720
  • 5
    • 0142087597 scopus 로고    scopus 로고
    • Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study
    • The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
    • The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-2167.
    • (2003) JAMA , vol.290 , pp. 2159-2167
  • 6
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
    • (1998) Lancet , vol.352 , pp. 837-853
  • 7
    • 33645061521 scopus 로고    scopus 로고
    • Evidence for renoprotection by blockade of the renin-angiotensin- aldosterone system in hypertension and diabetes
    • Karalliedde J, Viberti G. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens 2006;20: 239-253.
    • (2006) J Hum Hypertens , vol.20 , pp. 239-253
    • Karalliedde, J.1    Viberti, G.2
  • 8
    • 42749099562 scopus 로고    scopus 로고
    • Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease
    • Art. No.CD006257
    • Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006;Issue 4, Art. No.CD006257.
    • (2006) Cochrane Database Syst Rev , Issue.4
    • Strippoli, G.F.1    Bonifati, C.2    Craig, M.3    Navaneethan, S.D.4    Craig, J.C.5
  • 9
    • 84858316646 scopus 로고    scopus 로고
    • The impact of reninangiotensin-aldosterone system inhibitors on type 1 and type 2 diabetic patients with and without early diabetic nephropathy
    • Hirst JA, Taylor KS, Stevens RJ, et al. The impact of reninangiotensin- aldosterone system inhibitors on type 1 and type 2 diabetic patients with and without early diabetic nephropathy. Kidney Int 2012;81:674-683.
    • (2012) Kidney Int , vol.81 , pp. 674-683
    • Hirst, J.A.1    Taylor, K.S.2    Stevens, R.J.3
  • 10
    • 38049139424 scopus 로고    scopus 로고
    • Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease
    • Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30-48.
    • (2008) Ann Intern Med , vol.148 , pp. 30-48
    • Kunz, R.1    Friedrich, C.2    Wolbers, M.3    Mann, J.F.4
  • 12
    • 0035922441 scopus 로고    scopus 로고
    • Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    • Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
    • (2001) N Engl J Med , vol.345 , pp. 861-869
    • Brenner, B.M.1    Cooper, M.E.2    De Zeeuw, D.3
  • 13
    • 0035922447 scopus 로고    scopus 로고
    • Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
    • Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
    • (2001) N Engl J Med , vol.345 , pp. 851-860
    • Lewis, E.J.1    Hunsicker, L.G.2    Clarke, W.R.3
  • 14
    • 84856703024 scopus 로고    scopus 로고
    • Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: A systematic review and network meta-analysis
    • Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 2012;55: 566-578.
    • (2012) Diabetologia , vol.55 , pp. 566-578
    • Vejakama, P.1    Thakkinstian, A.2    Lertrattananon, D.3    Ingsathit, A.4    Ngarmukos, C.5    Attia, J.6
  • 17
    • 84879560586 scopus 로고    scopus 로고
    • Possible mechanisms of local tissue renin-angiotensin system activation in the cardiorenal metabolic syndrome and type 2 diabetes mellitus
    • Hayden MR, Sowers KM, Pulakat L, et al. Possible mechanisms of local tissue renin-angiotensin system activation in the cardiorenal metabolic syndrome and type 2 diabetes mellitus. Cardiorenal Med 2011;1:193-210.
    • (2011) Cardiorenal Med , vol.1 , pp. 193-210
    • Hayden, M.R.1    Sowers, K.M.2    Pulakat, L.3
  • 18
    • 4944251740 scopus 로고    scopus 로고
    • Advances in pathogenetic mechanisms of diabetic nephropathy
    • Nicholas SB. Advances in pathogenetic mechanisms of diabetic nephropathy. Cell Mol Biol (Noisy-le-grand) 2003;49:1319-1325.
    • (2003) Cell Mol Biol (Noisy-le-grand) , vol.49 , pp. 1319-1325
    • Nicholas, S.B.1
  • 20
    • 34748859681 scopus 로고    scopus 로고
    • The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease
    • Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007;59:251-287.
    • (2007) Pharmacol Rev , vol.59 , pp. 251-287
    • Kobori, H.1    Nangaku, M.2    Navar, L.G.3    Nishiyama, A.4
  • 21
    • 84860296188 scopus 로고    scopus 로고
    • Loss of angiotensin-converting enzyme 2 enhances TGF-beta/Smadmediated renal fibrosis and NF-kappaB-driven renal inflammation in a mouse model of obstructive nephropathy
    • Liu Z, Huang XR, Chen HY, Penninger JM, Lan HY. Loss of angiotensin-converting enzyme 2 enhances TGF-beta/Smadmediated renal fibrosis and NF-kappaB-driven renal inflammation in a mouse model of obstructive nephropathy. Lab Invest 2012;92:650-661.
    • (2012) Lab Invest , vol.92 , pp. 650-661
    • Liu, Z.1    Huang, X.R.2    Chen, H.Y.3    Penninger, J.M.4    Lan, H.Y.5
  • 22
    • 84863153340 scopus 로고    scopus 로고
    • Angiotensin II induces epithelial- to-mesenchymal transition in renal epithelial cells through reactive oxygen species/Src/caveolin-mediated activation of an epidermal growth factor receptor-extracellular signal-regulated kinase signaling pathway
    • Chen J, Chen JK, Harris RC. Angiotensin II induces epithelial- to-mesenchymal transition in renal epithelial cells through reactive oxygen species/Src/caveolin-mediated activation of an epidermal growth factor receptor-extracellular signal-regulated kinase signaling pathway. Mol Cell Biol 2012;32:981-991.
    • (2012) Mol Cell Biol , vol.32 , pp. 981-991
    • Chen, J.1    Chen, J.K.2    Harris, R.C.3
  • 23
    • 84859910851 scopus 로고    scopus 로고
    • Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats
    • Sofue T, Kiyomoto H, Kobori H, et al. Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. Am J Hypertens 2012;25:604-611.
    • (2012) Am J Hypertens , vol.25 , pp. 604-611
    • Sofue, T.1    Kiyomoto, H.2    Kobori, H.3
  • 24
    • 0033018804 scopus 로고    scopus 로고
    • Altered pressurenatriuresis in obese Zucker rats
    • Fujiwara K, Hayashi K, Matsuda H, et al. Altered pressurenatriuresis in obese Zucker rats. Hypertension 1999;33:1470-1475.
    • (1999) Hypertension , vol.33 , pp. 1470-1475
    • Fujiwara, K.1    Hayashi, K.2    Matsuda, H.3
  • 25
    • 78349232816 scopus 로고    scopus 로고
    • Population based screening for chronic kidney disease: Cost effectiveness study
    • Manns B, Hemmelgarn B, Tonelli M, et al. Population based screening for chronic kidney disease: cost effectiveness study. BMJ 2010;341:c5869.
    • (2010) BMJ , vol.341
    • Manns, B.1    Hemmelgarn, B.2    Tonelli, M.3
  • 26
    • 84859784009 scopus 로고    scopus 로고
    • Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: A systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline
    • Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2012;156:570-581.
    • (2012) Ann Intern Med , vol.156 , pp. 570-581
    • Fink, H.A.1    Ishani, A.2    Taylor, B.C.3
  • 27
    • 84874644599 scopus 로고    scopus 로고
    • KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease
    • Kidney Disease: Improving Global Outcomes (KDIGO)
    • Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013;3: 1-150.
    • (2013) Kidney Int , vol.3 , pp. 1-150
  • 28
    • 33845760213 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease
    • National Kidney Foundation
    • National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49(Suppl 2):S1-S180.
    • (2007) Am J Kidney Dis , vol.49 , Issue.SUPPL. 2
  • 29
    • 84867497463 scopus 로고    scopus 로고
    • KDOQI clinical practice guideline for diabetes and CKD: 2012 update
    • National Kidney Foundation
    • National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60:850-886.
    • (2012) Am J Kidney Dis , vol.60 , pp. 850-886
  • 30
    • 84874656078 scopus 로고    scopus 로고
    • KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease
    • Kidney Disease: Improving Global Outcomes (KDIGO)
    • Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2012;2:337-414.
    • (2012) Kidney Int , vol.2 , pp. 337-414
  • 32
    • 33747120659 scopus 로고    scopus 로고
    • Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate
    • Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254.
    • (2006) Ann Intern Med , vol.145 , pp. 247-254
    • Levey, A.S.1    Coresh, J.2    Greene, T.3
  • 33
    • 65649142017 scopus 로고    scopus 로고
    • A new equation to estimate glomerular filtration rate
    • Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
    • (2009) Ann Intern Med , vol.150 , pp. 604-612
    • Levey, A.S.1    Stevens, L.A.2    Schmid, C.H.3
  • 34
    • 0024370790 scopus 로고
    • Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program
    • The Hypertension Detection and Followup Program Cooperative Group
    • Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Followup Program Cooperative Group. Hypertension 1989;13:I80-I93.
    • (1989) Hypertension , vol.13
    • Shulman, N.B.1    Ford, C.E.2    Hall, W.D.3
  • 35
    • 0026481126 scopus 로고
    • Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects
    • Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. JAMA 1992;268(21):3085-3091.
    • (1992) JAMA , vol.268 , Issue.21 , pp. 3085-3091
    • Walker, W.G.1    Neaton, J.D.2    Cutler, J.A.3    Neuwirth, R.4    Cohen, J.D.5
  • 36
    • 0028953319 scopus 로고
    • Early predictors of 15-year end-stage renal disease in hypertensive patients
    • Perry HM Jr, Miller JP, Fornoff JR, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995;25:587-594.
    • (1995) Hypertension , vol.25 , pp. 587-594
    • Perry Jr., H.M.1    Miller, J.P.2    Fornoff, J.R.3
  • 37
    • 0141789624 scopus 로고    scopus 로고
    • Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis
    • Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244-252.
    • (2003) Ann Intern Med , vol.139 , pp. 244-252
    • Jafar, T.H.1    Stark, P.C.2    Schmid, C.H.3
  • 38
    • 84879596479 scopus 로고    scopus 로고
    • Kidney Disease Improving Global Outcomes (KDIGO), Available from, Accessed July 13
    • Kidney Disease Improving Global Outcomes (KDIGO). KDIGO reaches consensus on CKD staging. Available from http://www.kdigo.org/news-KDIGO-Consensus-on- CKD-Staging.php. Accessed July 13, 2012.
    • (2012) KDIGO Reaches Consensus on CKD Staging
  • 39
    • 84862774040 scopus 로고    scopus 로고
    • Kidney Disease Improving Global Outcomes (KDIGO), Available from, Accessed July 13
    • Kidney Disease Improving Global Outcomes (KDIGO). Kidney Disease: Improving Global Outcomes (KDIGO). Available from http://www.kdigo.org/clinical- practice-guidelines/ckd.phpews-KDIGO-Consensus-on-CKD-Staging.php. Accessed July 13, 2012.
    • (2012) Kidney Disease: Improving Global Outcomes (KDIGO)
  • 40
    • 84879576255 scopus 로고    scopus 로고
    • Kidney Disease Improving Global Outcomes (KDIGO), Available from, Accessed July 10
    • Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guidelines: published KDIGO clinical practice guidelines. Available from http://www.kdigo.org/clinical-practice-guidelines/index.php. Accessed July 10, 2012.
    • (2012) Clinical Practice Guidelines: Published KDIGO Clinical Practice Guidelines
  • 41
    • 77951735232 scopus 로고    scopus 로고
    • Effects of intensive blood-pressure control in type 2 diabetes mellitus
    • Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585.
    • (2010) N Engl J Med , vol.362 , pp. 1575-1585
    • Cushman, W.C.1    Evans, G.W.2    Byington, R.P.3
  • 42
    • 0035816018 scopus 로고    scopus 로고
    • Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial
    • Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285:2719-2728.
    • (2001) JAMA , vol.285 , pp. 2719-2728
    • Agodoa, L.Y.1    Appel, L.2    Bakris, G.L.3
  • 43
    • 9844219732 scopus 로고    scopus 로고
    • Effects of blood pressure control on progressive renal disease in blacks and whites
    • Modification of Diet in Renal Disease Study Group
    • Hebert LA, Kusek JW, Greene T, et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension 1997;30:428-435.
    • (1997) Hypertension , vol.30 , pp. 428-435
    • Hebert, L.A.1    Kusek, J.W.2    Greene, T.3
  • 44
    • 20244371503 scopus 로고    scopus 로고
    • Renal outcomes in high-risk hypertensive patients treated with an angiotensinconverting enzyme inhibitor or a calcium channel blocker vs a diuretic
    • A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensinconverting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:936-946.
    • (2005) Arch Intern Med , vol.165 , pp. 936-946
    • Rahman, M.1    Pressel, S.2    Davis, B.R.3
  • 45
    • 33644855606 scopus 로고    scopus 로고
    • Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate
    • Rahman M, Pressel S, Davis BR, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006;144:172-180.
    • (2006) Ann Intern Med , vol.144 , pp. 172-180
    • Rahman, M.1    Pressel, S.2    Davis, B.R.3
  • 46
    • 84055172779 scopus 로고    scopus 로고
    • Safety and efficacy of low blood pressures among patients with diabetes: Subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial)
    • Redon J, Mancia G, Sleight P, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol 2012;59:74-83.
    • (2012) J Am Coll Cardiol , vol.59 , pp. 74-83
    • Redon, J.1    Mancia, G.2    Sleight, P.3
  • 47
    • 77954374543 scopus 로고    scopus 로고
    • Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease
    • Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-68.
    • (2010) JAMA , vol.304 , pp. 61-68
    • Cooper-DeHoff, R.M.1    Gong, Y.2    Handberg, E.M.3
  • 48
    • 85037107344 scopus 로고    scopus 로고
    • National Institutes of Health, Available from, Accessed July 11
    • National Institutes of Health. Systolic Blood Pressure Intervention Trial (SPRINT). Available from http://clinicaltrials.gov/ct2/show/NCT01206062. Accessed July 11, 2012.
    • (2012) Systolic Blood Pressure Intervention Trial (SPRINT)
  • 49
    • 84862751530 scopus 로고    scopus 로고
    • Healthy People 2020, Available from, Accessed July 13
    • Healthy People 2020. Healthy People 2020 Topics and Objectives: Chronic Kidney Disease. Available from http://www.healthypeople.gov/2020/ topicsobjectives2020/objectiveslist.aspx?topicid=6. Accessed July 13, 2012.
    • (2012) Healthy People 2020 Topics and Objectives: Chronic Kidney Disease
  • 50
    • 67649635807 scopus 로고    scopus 로고
    • Renal and retinal effects of enalapril and losartan in type 1 diabetes
    • Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51.
    • (2009) N Engl J Med , vol.361 , pp. 40-51
    • Mauer, M.1    Zinman, B.2    Gardiner, R.3
  • 51
    • 67649659279 scopus 로고    scopus 로고
    • Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: Three randomized trials
    • Bilous R, Chaturvedi N, Sjolie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009;151:11-14.
    • (2009) Ann Intern Med , vol.151 , pp. 11-14
    • Bilous, R.1    Chaturvedi, N.2    Sjolie, A.K.3
  • 52
    • 82455162519 scopus 로고    scopus 로고
    • Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: A multicentre, randomised, placebo-controlled study
    • Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 2011;54:2978-2986.
    • (2011) Diabetologia , vol.54 , pp. 2978-2986
    • Imai, E.1    Chan, J.C.2    Ito, S.3
  • 53
    • 79952373965 scopus 로고    scopus 로고
    • Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
    • Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-917.
    • (2011) N Engl J Med , vol.364 , pp. 907-917
    • Haller, H.1    Ito, S.2    Izzo Jr., J.L.3
  • 55
    • 34247210073 scopus 로고    scopus 로고
    • Microalbuminuria: What is it? Why is it important? What should be done about it? An update
    • Chugh A, Bakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? An update J Clin Hypertens (Greenwich) 2007;9:196-200.
    • (2007) J Clin Hypertens (Greenwich) , vol.9 , pp. 196-200
    • Chugh, A.1    Bakris, G.L.2
  • 56
    • 67650451498 scopus 로고    scopus 로고
    • Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration
    • Levey AS, Cattran D, Friedman A, et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009;54:205-226.
    • (2009) Am J Kidney Dis , vol.54 , pp. 205-226
    • Levey, A.S.1    Cattran, D.2    Friedman, A.3
  • 57
    • 0032525867 scopus 로고    scopus 로고
    • Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial
    • Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998;128:982-988.
    • (1998) Ann Intern Med , vol.128 , pp. 982-988
    • Ravid, M.1    Brosh, D.2    Levi, Z.3    Bar-Dayan, Y.4    Ravid, D.5    Rachmani, R.6
  • 58
    • 77955518102 scopus 로고    scopus 로고
    • Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: A randomised crossover trial
    • Persson F, Rossing P, Reinhard H, et al. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia 2010;53:1576-1580.
    • (2010) Diabetologia , vol.53 , pp. 1576-1580
    • Persson, F.1    Rossing, P.2    Reinhard, H.3
  • 60
    • 33645069186 scopus 로고    scopus 로고
    • Prevention of loss of renal function over time in patients with diabetic nephropathy
    • Barnett A. Prevention of loss of renal function over time in patients with diabetic nephropathy. Am J Med 2006;119:S40-S47.
    • (2006) Am J Med , vol.119
    • Barnett, A.1
  • 61
    • 58249108731 scopus 로고    scopus 로고
    • Dual blockade of the renin-angiotensin system for cardiorenal protection: An update
    • Arici M, Erdem Y. Dual blockade of the renin-angiotensin system for cardiorenal protection: an update. Am J Kidney Dis 2009;53:332-345.
    • (2009) Am J Kidney Dis , vol.53 , pp. 332-345
    • Arici, M.1    Erdem, Y.2
  • 62
    • 0037431774 scopus 로고    scopus 로고
    • Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE): A randomised controlled trial
    • Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-124.
    • (2003) Lancet , vol.361 , pp. 117-124
    • Nakao, N.1    Yoshimura, A.2    Morita, H.3    Takada, M.4    Kayano, T.5    Ideura, T.6
  • 63
    • 70349771914 scopus 로고    scopus 로고
    • Retraction-Combination treatment of angiotensin- II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial
    • Anonymous
    • Anonymous. Retraction-Combination treatment of angiotensin- II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2009;374:1226.
    • (2009) Lancet , vol.374 , pp. 1226
  • 64
    • 18244406792 scopus 로고    scopus 로고
    • Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension
    • Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005;45:880-886.
    • (2005) Hypertension , vol.45 , pp. 880-886
    • Doulton, T.W.1    He, F.J.2    MacGregor, G.A.3
  • 65
    • 34648820103 scopus 로고    scopus 로고
    • Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial
    • Bakris GL, Ruilope L, Locatelli F, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007;72:879-885.
    • (2007) Kidney Int , vol.72 , pp. 879-885
    • Bakris, G.L.1    Ruilope, L.2    Locatelli, F.3
  • 66
    • 49149087718 scopus 로고    scopus 로고
    • Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial
    • Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double- blind, controlled trial. Lancet 2008;372:547-553.
    • (2008) Lancet , vol.372 , pp. 547-553
    • Mann, J.F.1    Schmieder, R.E.2    McQueen, M.3
  • 67
    • 66649094130 scopus 로고    scopus 로고
    • Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy
    • Krairittichai U, Chaisuvannarat V. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy. J Med Assoc Thai 2009;92:611-617.
    • (2009) J Med Assoc Thai , vol.92 , pp. 611-617
    • Krairittichai, U.1    Chaisuvannarat, V.2
  • 69
    • 67249125166 scopus 로고    scopus 로고
    • The hazards of dual renin-angiotensin blockade in chronic kidney disease
    • Ku E, Park J, Vidhun J, Campese V. The hazards of dual renin-angiotensin blockade in chronic kidney disease. Arch Intern Med 2009;169:1015-1018.
    • (2009) Arch Intern Med , vol.169 , pp. 1015-1018
    • Ku, E.1    Park, J.2    Vidhun, J.3    Campese, V.4
  • 70
    • 70349337020 scopus 로고    scopus 로고
    • Proteinuria: Is the ONTARGET renal substudy actually off target?
    • Ruggenenti P, Remuzzi G. Proteinuria: is the ONTARGET renal substudy actually off target? Nat Rev Nephrol 2009;5:436-437.
    • (2009) Nat Rev Nephrol , vol.5 , pp. 436-437
    • Ruggenenti, P.1    Remuzzi, G.2
  • 71
    • 66849128220 scopus 로고    scopus 로고
    • Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D)
    • Fried LF, Duckworth W, Zhang JH, et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009;4:361-368.
    • (2009) Clin J Am Soc Nephrol , vol.4 , pp. 361-368
    • Fried, L.F.1    Duckworth, W.2    Zhang, J.H.3
  • 72
    • 84879586859 scopus 로고    scopus 로고
    • National Institutes of Health, Available from, Accessed July 10
    • National Institutes of Health. VA NEPHRON-D: Diabetes iN Nephropathy Study. Available from http://clinicaltrials.gov/ct2/show/results/NCT00555217. Accessed July 10, 2012.
    • (2012) VA NEPHRON-D: Diabetes iN Nephropathy Study
  • 73
    • 78649929199 scopus 로고    scopus 로고
    • Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy
    • Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care 2010;33:2304-2309.
    • (2010) Diabetes Care , vol.33 , pp. 2304-2309
    • Persson, F.1    Lewis, J.B.2    Lewis, E.J.3    Rossing, P.4    Hollenberg, N.K.5    Parving, H.H.6
  • 74
    • 65249182083 scopus 로고    scopus 로고
    • Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): Rationale and study design
    • Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24:1663-1671.
    • (2009) Nephrol Dial Transplant , vol.24 , pp. 1663-1671
    • Parving, H.H.1    Brenner, B.M.2    McMurray, J.J.3
  • 77
    • 34548084570 scopus 로고    scopus 로고
    • Normotensive ischemic acute renal failure
    • Abuelo JG. Normotensive ischemic acute renal failure. N Engl J Med 2007;357:797-805.
    • (2007) N Engl J Med , vol.357 , pp. 797-805
    • Abuelo, J.G.1
  • 78
    • 80051801008 scopus 로고    scopus 로고
    • Role of collaborative care models including pharmacists in improving blood pressure management in chronic kidney disease patients
    • St Peter WL, Farley TM, Carter BL. Role of collaborative care models including pharmacists in improving blood pressure management in chronic kidney disease patients. Curr Opin Nephrol Hypertens 2011;20:498-503.
    • (2011) Curr Opin Nephrol Hypertens , vol.20 , pp. 498-503
    • St Peter, W.L.1    Farley, T.M.2    Carter, B.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.